Pegylated Liposomal Doxorubicin in Combination with Hyperthermia for Treatment of Skin Metastases of Breast Carcinoma: A Case Report

2001 ◽  
Vol 24 (2) ◽  
pp. 166-168 ◽  
Author(s):  
J. Dvořák ◽  
Z. Zoul ◽  
B. Melichar ◽  
P. Jandík ◽  
J. Mergancová ◽  
...  
Keyword(s):  
Case Report ◽  
Breast Carcinoma ◽  
Liposomal Doxorubicin ◽  
Pegylated Liposomal Doxorubicin ◽  
Skin Metastases

scholarly journals Pulmonary Fibrosis after Pegylated Liposomal Doxorubicin in Elderly Patient with Cutaneous Angiosarcoma

2016 ◽  
Vol 2016 ◽  
pp. 1-5 ◽  
Author(s):  
Marco Mazzotta ◽  
Raffaele Giusti ◽  
Daniela Iacono ◽  
Salvatore Lauro ◽  
Paolo Marchetti
Keyword(s):  
Elderly Patient ◽  
Case Report ◽  
Pulmonary Fibrosis ◽  
Pulmonary Toxicity ◽  
Liposomal Doxorubicin ◽  
Pegylated Liposomal Doxorubicin ◽  
The Body ◽  
Rare Cancer ◽  
True Incidence ◽  
First Case

Introduction. Angiosarcoma is a rare cancer of the inner lining of blood vessels and can arise anywhere in the body, most commonly presenting as cutaneous disease in elderly patient, involving head and neck (H&N), especially the scalp. Pegylated liposomal doxorubicin (PLD) is one of the available treatments in patients with advanced or metastatic disease. Common toxicities are myelosuppression, palmar-plantar erythrodysesthesia, nausea, and stomatitis. Regarding PLD-related pulmonary fibrosis in an uncommon toxicity, there are few cases reported in literature. None of these occurred in angiosarcoma.Methods. This is a case report describing an elderly patient treated with PLD for advanced H&N cutaneous angiosarcoma who developed G5 pulmonary toxicity after the second PLD administration.Results. According to our data and patient clinical outcome, we believe that she passed away from fatal PLD-induced pulmonary fibrosis. This is the first case of fatal interstitial pneumonitis in a 77-year-old woman treated with PLD for angiosarcoma. The case has been reported for its rarity.Conclusions. Pathophysiology of this phenomenon is still unclear and more studies are necessary to understand the true incidence of pulmonary toxicities in patients in treatments with PLD and its mechanism.

scholarly journals Histological evidence for the cardiac safety of high-dose pegylated liposomal doxorubicin in a patient with HIV-associated Kaposi sarcoma: a case report and literature review

2019 ◽  
Vol 19 (1) ◽  
Author(s):  
Ayaka Ishihara ◽  
Shuji Hatakeyama ◽  
Jun Suzuki ◽  
Yusuke Amano ◽  
Teppei Sasahara ◽  
...  
Keyword(s):  
Case Report ◽  
Literature Review ◽  
Cumulative Dose ◽  
Liposomal Doxorubicin ◽  
Cardiac Toxicity ◽  
Pegylated Liposomal Doxorubicin ◽  
Kaposi Sarcoma ◽  
Left Ventricular ◽  
Left Ventricular Ejection ◽  
Ventricular Ejection Fraction

Abstract Background Pegylated liposomal doxorubicin plays an important role in the treatment of patients with severe refractory human immunodeficiency virus (HIV)-associated Kaposi sarcoma (KS). High cumulative doses of conventional doxorubicin exceeding 500 mg/m2 are known to cause cardiac toxicity. However, the safe cumulative dose of pegylated liposomal doxorubicin is unclear. Case presentation A 40-year-old Japanese man with HIV infection presented with pain, edema, and multiple skin nodules on both legs which worsened over several months. He was diagnosed with HIV-associated KS. He received long-term pegylated liposomal doxorubicin combined with antiretroviral therapy for advanced, progressive KS. The cumulative dose of pegylated liposomal doxorubicin reached 980 mg/m2. The patient’s left ventricular ejection fraction remained unchanged from baseline during treatment. After he died as a result of cachexia and wasting, caused by recurrent sepsis and advanced KS, an autopsy specimen of his heart revealed little or no evidence of histological cardiac damage. We also conducted a literature review focusing on histological changes of the myocardium in patients treated with a cumulative dose of pegylated liposomal doxorubicin exceeding 500 mg/m2. Conclusions This case report and literature review suggest that high (> 500 mg/m2) cumulative doses of pegylated liposomal doxorubicin may be used without significant histological/clinical cardiac toxicity in patients with HIV-associated KS.

Pegylated Liposomal Doxorubicin with Vinorelbine in Metastatic Breast Carcinoma

Oncology ◽  
2002 ◽  
Vol 63 (1) ◽  
pp. 23-30 ◽  
Author(s):  
Vittorio Gebbia ◽  
Gaetano Mauceri ◽  
Giuseppina Fallica ◽  
Nicolò Borsellino ◽  
Maria Lina Tirrito ◽  
...  
Keyword(s):  
Breast Carcinoma ◽  
Liposomal Doxorubicin ◽  
Metastatic Breast ◽  
Pegylated Liposomal Doxorubicin ◽  
Metastatic Breast Carcinoma

scholarly journals Bradycardia associated with pegylated liposomal doxorubicin administration: a case report

2016 ◽  
Vol 24 (2) ◽  
pp. 128-130 ◽  
Author(s):  
Zhaolu Xie ◽  
Wei Wu ◽  
Haiyan Xing ◽  
Yongqing Cai ◽  
Xianfeng Wang ◽  
...  
Keyword(s):  
Case Report ◽  
Liposomal Doxorubicin ◽  
Pegylated Liposomal Doxorubicin ◽  
Doxorubicin Administration

scholarly journals Weekly pegylated liposomal doxorubicin and paclitaxel in patients with metastatic breast carcinoma: A phase II study

2010 ◽  
Vol 1 (4) ◽  
pp. 749-753 ◽  
Author(s):  
VITA LEONARDI ◽  
VALENTINA PALMISANO ◽  
ALESSIO PEPE ◽  
ANTONELLA USSET ◽  
GIOVANNA MANUGUERRA ◽  
...  
Keyword(s):  
Breast Carcinoma ◽  
Phase Ii ◽  
Liposomal Doxorubicin ◽  
Phase Ii Study ◽  
Metastatic Breast ◽  
Pegylated Liposomal Doxorubicin ◽  
Metastatic Breast Carcinoma
Sign in / Sign up

Export Citation Format

Share Document